Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer

Publication date: May 2018
Source:Radiologic Clinics of North America, Volume 56, Issue 3
Author(s): Girish S. Shroff, Patricia M. de Groot, Vassiliki A. Papadimitrakopoulou, Mylene T. Truong, Brett W. Carter

Teaser

The treatment strategy in advanced non–small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.


from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2q6GOUa